Clinical Trials for Non-Small Cell Lung Cancer

543 non-small cell lung cancer trials indexed, 269 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It originates in the epithelial cells of the lung and tends to grow and spread more slowly than small cell lung cancer. NSCLC is a group of lung cancers that includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Diagnosis typically involves imaging tests such as chest X-rays or CT scans, followed by a biopsy to confirm the presence of cancer cells and determine the specific subtype. Molecular testing is often performed on biopsy samples to identify genetic mutations that can influence treatment options.

Common symptoms of NSCLC include a persistent cough, chest pain, shortness of breath, and coughing up blood. Other signs may include unexplained weight loss and fatigue. The disease most often affects adults aged 65 and older, but it can occur in younger individuals as well. Smoking is the leading risk factor, responsible for most cases, but exposure to radon gas, asbestos, air pollution, and a family history of lung cancer also increase risk. NSCLC can develop even in people who have never smoked, especially adenocarcinoma, which is more common in non-smokers and women.

NSCLC has a significant medical and social impact. It is one of the leading causes of cancer-related deaths worldwide. In the United States alone, NSCLC accounts for about 80% of all lung cancer deaths. Early diagnosis is challenging because symptoms often appear late, contributing to a high mortality rate. According to recent data, lung cancer’s five-year survival rate remains under 25%, highlighting the need for better detection and treatment strategies. The economic burden is also substantial, including costs for medical care, lost productivity, and long-term disability.

The Non-Small Cell Lung Cancer Treatment Landscape

The first-line treatment for NSCLC depends on the stage and specific characteristics of the tumor. Early-stage NSCLC is often treated with surgery to remove the tumor, sometimes followed by radiation therapy to eliminate remaining cancer cells. For more advanced stages, chemotherapy is commonly used, often combined with radiation or targeted therapies. Immunotherapy has become an important part of first-line treatment for certain patients, especially those with tumors expressing high levels of PD-L1, a protein that helps cancer cells evade the immune system. Treatment plans are usually tiered based on tumor genetics, stage, and patient health.

When the cancer progresses or does not respond to initial therapies, second- and third-line treatments come into play. These options include additional chemotherapy agents, targeted therapies that block specific mutations like EGFR or ALK, and immunotherapy drugs such as checkpoint inhibitors. Common drug classes used in later lines include tyrosine kinase inhibitors and monoclonal antibodies. Examples of drugs used in these settings are osimertinib for EGFR mutations and pembrolizumab for immunotherapy. The choice depends on prior treatments and molecular test results.

Despite advances, there are still significant gaps in NSCLC treatment. Some patient subgroups, such as those with rare mutations or low PD-L1 expression, respond poorly to available therapies. Resistance to targeted drugs and immunotherapies often develops, limiting long-term effectiveness. Side effects from chemotherapy and immunotherapy can be severe, affecting quality of life. Research is focusing on overcoming resistance mechanisms, finding new targets for therapy, and developing treatments with fewer side effects. Clinical trials play a key role in exploring these new options.

Why Clinical Trials Matter for Non-Small Cell Lung Cancer

Clinical trials offer patients with NSCLC access to new treatments that are not yet widely available. These trials test novel drugs, combinations, or approaches to improve outcomes. Patients in trials often receive closer monitoring and comprehensive care during the study period. According to ClinicalTrials.gov, there are currently 543 NSCLC clinical trials indexed, with 269 actively recruiting participants. This large number reflects ongoing efforts to find better therapies and improve survival rates for people affected by this disease.

Participating in a clinical trial involves certain risks. The effectiveness of the experimental treatment is not guaranteed, and some patients may receive a placebo or standard therapy instead of the new drug. Additional clinic visits, tests, and procedures are often required, which can be time-consuming and inconvenient. Side effects may arise from the investigational treatment, and their severity can vary. Patients should carefully consider these factors and discuss them with their healthcare team before enrolling.

The NSCLC clinical trial landscape includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative groups. Academic centers often focus on early-stage research and novel therapies, while industry sponsors conduct larger trials to gain regulatory approval. Cooperative groups bring together multiple institutions to run large, multi-center studies. ClinicalTrials.gov serves as a centralized registry where patients, caregivers, and healthcare providers can find detailed information about ongoing trials, eligibility criteria, and locations. This transparency helps people make informed decisions about participation.

What to Look for in a Non-Small Cell Lung Cancer Clinical Trial

Clinical trials are divided into four main phases. Phase 1 trials focus on testing the safety of a new drug or treatment in a small group of people. Phase 2 trials look at how well the treatment works and further evaluate its safety. Phase 3 trials compare the new treatment to the current standard treatment in larger groups. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For Non-Small Cell Lung Cancer, there are 543 trials listed. Among these, 187 are Phase 1, 137 are Phase 2, 101 are Phase 3, and 39 have no phase listed. Phase 1 trials are the most common in this area.

To join a Non-Small Cell Lung Cancer trial, patients usually must meet specific inclusion criteria. These often include age limits, such as adults 18 years or older. Patients may need to have certain stages of cancer, like stage III or IV, or specific types of tumors. Some trials require prior treatments to have been tried, while others are for newly diagnosed patients. Biomarkers, which are biological signs found in tumors or blood, can also be important. For example, some trials look for mutations in genes like EGFR or ALK. The length of time since diagnosis or last treatment may also affect eligibility.

Exclusion criteria help keep patients safe and ensure clear results. Patients with other serious health problems, such as heart disease or uncontrolled infections, may be excluded. Drug interactions are a concern, so people taking certain medications might not qualify. Safety thresholds like blood counts, liver, and kidney function are checked before participation. These rules help protect patients from harm and avoid complications that could affect the study findings.

Participating in a trial requires thinking about practical details. Trial duration can vary from a few weeks to several months or years. Visit schedules might be frequent, especially in early phases, requiring travel to the study site. Patients should ask the research team key questions before joining. These include: How many visits will I need? What tests and procedures will I undergo? What are the possible side effects? How will this trial affect my current treatment plan? Understanding these details helps patients and caregivers make informed decisions.

Primary Sources and Further Reading

For more detailed information about Non-Small Cell Lung Cancer and clinical trials, it is important to consult reliable sources. These websites provide trustworthy and up-to-date content on cancer treatments, research, and patient support. They can help you learn more about clinical trials and how to find one that fits your needs.

• National Cancer Institute: Non-Small Cell Lung Cancer Treatment
• ClinicalTrials.gov: Non-Small Cell Lung Cancer Trials
• MedlinePlus: Lung Cancer Information
• Centers for Disease Control and Prevention: Lung Cancer

Latest Research and Emerging Treatments for Non-Small Cell Lung Cancer (2026)

Non-small cell lung cancer treatment continues to evolve with ongoing clinical trials testing new drugs and combinations. One important Phase 3 trial is studying durvalumab combined with domvanalimab after chemoradiation in patients with locally advanced, unresectable non-small cell lung cancer (NCT05211895). Durvalumab is an immunotherapy drug that helps the immune system recognize and attack cancer cells. Domvanalimab works by blocking proteins that suppress immune responses, potentially boosting the effect of durvalumab. This combination aims to improve disease control and survival for patients who have limited options after chemoradiation.

Another area of research focuses on targeted therapies for specific genetic mutations. Zipalertinib is being tested with chemotherapy in patients with early-stage non-small cell lung cancer who have uncommon EGFR mutations (NCT07128199). EGFR mutations can cause cancer cells to grow uncontrollably. Zipalertinib may block this growth by targeting the mutated EGFR protein. If successful, this non-small cell lung cancer new treatment 2026 could help prevent cancer recurrence after surgery and improve disease-free survival.

For patients with advanced disease and RAS gene mutations, daraxonrasib is under study (NCT06881784). This drug targets the RAS protein, which is involved in cell growth and survival. Daraxonrasib is compared to standard chemotherapy to see if it offers better safety and effectiveness. Additionally, cemiplimab is being tested as an adjuvant immunotherapy after surgery for patients who have not received chemotherapy before (NCT06931717). Cemiplimab works by activating the immune system to attack remaining cancer cells and may help extend the time patients remain cancer-free. These trials highlight ongoing non-small cell lung cancer research focused on new drugs for non-small cell lung cancer that could provide more personalized and effective treatment options in 2026.

Frequently asked questions about Non-Small Cell Lung Cancer trials

How do I find Non-Small Cell Lung Cancer clinical trials?

The authoritative source for Non-Small Cell Lung Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 543 non-small cell lung cancer studies are currently indexed. You can search by entering "non-small cell lung cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new non-small cell lung cancer trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Non-Small Cell Lung Cancer trials in?

Across the 543 non-small cell lung cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Non-Small Cell Lung Cancer clinical trials are currently recruiting?

As of the latest scan, 269 non-small cell lung cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 543 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting non-small cell lung cancer trial matches their tracked condition.

Stay informed about non-small cell lung cancer research

Get a weekly briefing with the trials that matter most.

Start monitoring non-small cell lung cancer trials